UK Injectables Market Outlook to 2017

News provided by

Jan 08, 2014, 10:54 ET

LONDON, Jan. 8, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

UK Injectables Market Outlook to 2017

Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided immense growth opportunities for injectables to emerge in the UK's pharmaceutical industry in recent years. According to RNCOS' research report, "UK Injectables Market Outlook to 2017", the market is anticipated to grow at a CAGR of approximately 4.5% during 2012-2017. The increasing need of injectables for diseases like diabetes, infectious diseases and arthritis is primarily driving this market.

The said report is a study of the UK injectable market in terms of major therapeutic areas. It covers the historical sales trend of injectables for categories such as Diabetes, Vaccines, Sex Hormones & Antagonist in Malign Disease, Anticoagulants & Protamine, Hypothalamic & Pituitary Hormones, Rheumatic Diseases & Gout, etc. Not only this, the report also provides the sales trend of the top 10 injectable drugs in the UK market along with a rational analysis.

Certain pharmaceutical firms in UK's injectable market have established their foothold given the diverse and innovative product offerings. Several small pharma majors too have been aggressively competing with big pharmaceutical players in order to establish themselves in the market. The report highlights a detailed comparison of the market shares of different players in the injectables market.

The study provides an insight about the competitive landscape, which includes business profiling and a strength-weakness analysis of top pharmaceutical players in the UK injectable business. There's also a coverage of the detailed analysis of their top injectable drugs in terms of revenue.

A lot of investment is being done in research and development of injectables in order to improve their medical outcomes. Here it is worth mentioning that even the country's government has significantly contributed towards the development of innovative medicines.

Moreover, the Government has shifted its focus towards cost effective drug treatments by fixing up the drug prices as per their clinical value. In addition, there are a set of regulations that support the injectable drug business in the country. In this context, various regulatory processes such as drug licensing, marketing/ promotion, pricing etc. have been comprehensively covered in the report. In a nutshell, the report covers every aspect of UK injectables which will help the industry players to take strategic decisions.

1. Analyst View
2. Research Methodology
3. UK Injectables Market Outlook to 2017
3.1 Current and Future Market Analysis
3.1.1 By Top 10 Injectables
3.1.2 By Top 10 Therapeutics
3.1.3 By Major Players
4. Drivers and Challenges
4.1 Drivers
4.2 Challenges
5. Regulatory Environment
6. Competitive Landscape
6.1 Novo Nordisk
6.1.1 Business Overview
6.1.2 Key Injectable Sales
6.1.3 Strengths and Weaknesses
6.1.4 Recent Developments
6.2 Sanofi
6.2.1 Business Overview
6.2.2 Key Injectable Sales
6.2.3 Strengths and Weaknesses
6.2.4 Recent Developments
6.3 Eli Lily & Co.
6.3.1 Business Overview
6.3.2 Key Injectable Sales
6.3.3 Strengths and Weaknesses
6.4 Pfizer
6.4.1 Business Overview
6.4.2 Key Injectable Sales
6.4.3 Strengths and Weaknesses
6.4.4 Recent Developments
6.5 Abbott Laboratories
6.5.1 Business Overview
6.5.2 Key Injectable Sales
6.5.3 Strengths and Weaknesses
6.5.4 Recent Developments
6.6 Takeda Pharmaceutical Company Ltd
6.6.1 Business Overview
6.6.2 Key Injectable Sales
6.6.3 Strengths and Weaknesses
6.6.4 Recent Developments

List of Figures:

Figure 3-1: Injectables Market (Million £), 2012-2017
Figure 3-2: Injectables Market by Player (%), 2010
Figure 3-3: Injectables Market by Player (%), 2012
Figure 4-1: Novo Nordisk - Break up of Revenue by Business Segment (%), 2012
Figure 4-2: Novo Nordisk - Diabetes Care Revenue by Segment (%), 2012
Figure 4-3: Novo Nordisk UK - Break up of Revenue by Segment (%), 2012
Figure 4-4: Sanofi - Break up of Revenue by Business Segment (%), 2012
Figure 4-5: Eli Lily & Co. - Break up of Revenue by Business Segment (%), 2012
Figure 4-6: Eli Lily & Co. - Human Pharmaceutical Division Revenue by Segment (%), 2012
Figure 4-7: Pfizer - Break up of Revenue by Business Segment (%), 2012

List of Tables:

Table 3-1: Top 10 Injectable Sales (Million £), 2010-2012
Table 3-2: Injectable Sales by Top 10 Therapeutics (Million £), 2010-2012
Table 4-1: Novo Nordisk UK - Key Injectable Sales (Million £), 2010-2012
Table 4-2: Novo Nordisk UK - Strengths and Weaknesses
Table 4-3: Sanofi UK - Key Injectable Sales (Million £), 2010-2012
Table 4-4: Sanofi UK - Strengths and Weaknesses
Table 4-5: Eli Lily & Co. UK - Key Injectable Sales (Million £), 2010-2012
Table 4-6: Eli Lily & Co. UK - Strengths and Weaknesses
Table 4-7: Pfizer UK - Key Injectable Sales (Million £), 2010-2012
Table 4-8: Pfizer UK - Strengths and Weaknesses
Table 4-9: Abbott Laboratories UK - Key Injectable Sales (Million £), 2010-2012
Table 4-10: Abbott Laboratories UK - Strengths and Weaknesses
Table 4-11: Takeda Pharmaceuticals UK - Key Injectable Sales (Million £), 2010-2012
Table 4-12: Takeda Pharmaceuticals UK - Strengths and Weaknesses